3d ago
ProPharmaceutical: Announcement on the progress of repurchasing the company's shares
Securities code: 000739 Securities abbreviation: Puluo Pharmaceutical Announcement number: 2026-78
Prolo Pharmaceutical Co., Ltd.
Announcement on the progress of repurchasing the company's shares
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Pluto Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the fourth meeting of the 10th Board of Directors on June 11, 2026, and held the first extraordinary shareholders' meeting of 2026 on June 29, 2026. The "Proposal on Repurchasing the Company's Shares for Cancellation and Reduction of Registered Capital" was reviewed and approved, and the company agreed to use its own funds to repurchase part of the company's shares through centralized bidding transactions for cancellation and reduction of the company's registered capital. The price limit for repurchasing shares shall not exceed RMB 20 per share (inclusive), and the total repurchase funds shall not be less than RMB 100 million (inclusive) and not exceed RMB 150 million (inclusive). The specific number of shares repurchased shall be based on the actual number of shares repurchased when the repurchase period expires or the repurchase of shares is completed. The repurchase period is within 6 months from the date the company's shareholders meeting approves the share repurchase plan. For specific details, please refer to the relevant announcements disclosed by the company on June 12, 2026 and June 30, 2026 on the Juchao Information Network (www.cninfo.com.cn).
According to relevant regulations such as the "Share Repurchase Rules of Listed Companies" and "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 9 - Repurchase of Shares", companies should announce the progress of repurchases as of the end of the previous month within the first three trading days of each month. The progress of the company’s share repurchase is now announced as follows:
1. Progress of share repurchase
As of August 31, 2026, the company has repurchased 5,410,100 shares of the company through centralized bidding transactions through a special securities account for repurchase, accounting for 0.47% of the company's current total share capital. The highest transaction price is 19.98 yuan/share, the lowest transaction price is 17.05 yuan/share, and the total transaction amount is 99,989,732.95 yuan (excluding transaction fees). This repurchase complies with the company's share repurchase plan and the requirements of relevant laws and regulations.
2. Other instructions
The company's time for repurchasing shares, the number of shares repurchased, the price of repurchased shares and the entrustment time of centralized bidding transactions are all in compliance with the "Share Repurchase Rules for Listed Companies", "Shenzhen Stock Exchange Self-Discipline Supervision Guidelines for Listed Companies No. 9 - Share Repurchase" and the relevant provisions of the company's share repurchase plan.
- The company did not repurchase the company’s shares during the following periods:
(1) From the date when a major event that may have a significant impact on the trading price of the company's securities and its derivatives occurs or during the decision-making process, to the date of disclosure in accordance with the law;
(2) Other circumstances specified by the China Securities Regulatory Commission and Shenzhen Stock Exchange.
- The company’s share repurchase through centralized bidding transactions meets the following requirements:
(1) The entrusted price shall not be the price that limits the trading increase of the company’s stock on that day;
(2) No share repurchase entrustment shall be made during the opening call auction, closing call auction and trading days when the stock price has no limit on the price increase or decrease of the Shenzhen Stock Exchange;
(3) Other requirements stipulated by the China Securities Regulatory Commission and Shenzhen Stock Exchange.
The company will subsequently implement the share repurchase plan within the repurchase period based on the company's share repurchase plan and taking into account market conditions and the company's capital arrangements, and will perform its information disclosure obligations in a timely manner in strict accordance with relevant laws, regulations and normative documents. Investors are kindly requested to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Puluo Pharmaceutical Co., Ltd.
September 2, 2026